SE520645C2 - Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav - Google Patents
Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning däravInfo
- Publication number
- SE520645C2 SE520645C2 SE9604193A SE9604193A SE520645C2 SE 520645 C2 SE520645 C2 SE 520645C2 SE 9604193 A SE9604193 A SE 9604193A SE 9604193 A SE9604193 A SE 9604193A SE 520645 C2 SE520645 C2 SE 520645C2
- Authority
- SE
- Sweden
- Prior art keywords
- component
- composition according
- cyclodextrin
- skin
- beta
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000002537 cosmetic Substances 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 230000001225 therapeutic effect Effects 0.000 title description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 18
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940031439 squalene Drugs 0.000 claims abstract description 18
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 11
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 11
- 239000010686 shark liver oil Substances 0.000 claims abstract description 11
- 229940069764 shark liver oil Drugs 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 24
- 239000002674 ointment Substances 0.000 claims description 14
- 239000001116 FEMA 4028 Substances 0.000 claims description 13
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 13
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 13
- 229960004853 betadex Drugs 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 9
- -1 alkyl glycerols Chemical class 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 150000004697 chelate complex Chemical class 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 abstract description 3
- 229940032094 squalane Drugs 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 11
- 230000005855 radiation Effects 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000000536 complexating effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OOWQBDFWEXAXPB-IBGZPJMESA-N 1-O-hexadecyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)CO OOWQBDFWEXAXPB-IBGZPJMESA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- NRWMBHYHFFGEEC-MDZDMXLPSA-N 3-[(e)-octadec-9-enoxy]propane-1,2-diol Chemical compound CCCCCCCC\C=C\CCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-MDZDMXLPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OOWQBDFWEXAXPB-UHFFFAOYSA-N chimyl alcohol Natural products CCCCCCCCCCCCCCCCOCC(O)CO OOWQBDFWEXAXPB-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- NRWMBHYHFFGEEC-UHFFFAOYSA-N selachyl alcohol Natural products CCCCCCCCC=CCCCCCCCCOCC(O)CO NRWMBHYHFFGEEC-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604193A SE520645C2 (sv) | 1996-11-15 | 1996-11-15 | Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav |
| PL97333209A PL333209A1 (en) | 1996-11-15 | 1997-11-14 | Medical and cosmetic compositions, their applications and method of manufacturing |
| IL12953697A IL129536A0 (en) | 1996-11-15 | 1997-11-14 | Therapeutic and cosmetic compositions their use and method for the preparation thereof |
| DE69727507T DE69727507T2 (de) | 1996-11-15 | 1997-11-14 | Therapeutische und kosmetische mittel, ihre verwendung und herstellungsverfahren |
| NZ335473A NZ335473A (en) | 1996-11-15 | 1997-11-14 | Therapeutic and cosmetic compositions, their use and method for the preparation thereof |
| EP97913636A EP1014926B1 (de) | 1996-11-15 | 1997-11-14 | Therapeutische und kosmetische mittel, ihre verwendung und herstellungsverfahren |
| PCT/SE1997/001921 WO1998022083A1 (en) | 1996-11-15 | 1997-11-14 | Therapeutic and cosmetic compositions, their use and method for the preparation thereof |
| AU50773/98A AU727291B2 (en) | 1996-11-15 | 1997-11-14 | Therapeutic and cosmetic compositions, their use and method for the preparation thereof |
| AT97913636T ATE258783T1 (de) | 1996-11-15 | 1997-11-14 | Therapeutische und kosmetische mittel, ihre verwendung und herstellungsverfahren |
| CA002271268A CA2271268C (en) | 1996-11-15 | 1997-11-14 | Therapeutic and cosmetic compositions comprising an extract of crude shark liver oil, their use and method for the preparation thereof |
| NO19992030A NO313616B1 (no) | 1996-11-15 | 1999-04-28 | Terapeutiske og kosmetiske sammensetninger og deres anvendelse |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604193A SE520645C2 (sv) | 1996-11-15 | 1996-11-15 | Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9604193D0 SE9604193D0 (sv) | 1996-11-15 |
| SE9604193L SE9604193L (sv) | 1998-05-16 |
| SE520645C2 true SE520645C2 (sv) | 2003-08-05 |
Family
ID=20404626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9604193A SE520645C2 (sv) | 1996-11-15 | 1996-11-15 | Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1014926B1 (de) |
| AT (1) | ATE258783T1 (de) |
| AU (1) | AU727291B2 (de) |
| CA (1) | CA2271268C (de) |
| DE (1) | DE69727507T2 (de) |
| IL (1) | IL129536A0 (de) |
| NO (1) | NO313616B1 (de) |
| NZ (1) | NZ335473A (de) |
| PL (1) | PL333209A1 (de) |
| SE (1) | SE520645C2 (de) |
| WO (1) | WO1998022083A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801647D0 (sv) * | 1998-05-12 | 1998-05-12 | Interhealth Ab | Therapeutic composition |
| FR2782269B1 (fr) | 1998-08-17 | 2001-08-31 | Oreal | Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation |
| AU757896B2 (en) * | 1998-09-02 | 2003-03-13 | Allergan, Inc. | Preserved cyclodextrin-containing compositions |
| JP2000159678A (ja) * | 1998-11-30 | 2000-06-13 | Nof Corp | 皮膚外用剤組成物 |
| US7090859B2 (en) | 2002-12-13 | 2006-08-15 | Ronald Thomas Haas | Ketoprofen compositions and methods of making them |
| GB0519334D0 (en) * | 2005-09-22 | 2005-11-02 | Unichema Chemie Bv | Method and composition for treating skin |
| FR3017796B1 (fr) * | 2014-02-27 | 2017-03-24 | Etienne Soudant | Composition cosmetique a base de squalene comme substitut incolore aux carotenoides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3294639A (en) * | 1964-02-03 | 1966-12-27 | Eversharp Inc | Treatment of inflammatory diseases |
| JPS61227517A (ja) * | 1985-04-01 | 1986-10-09 | Lion Corp | 皮膚化粧料 |
| CA1321192C (en) * | 1988-04-20 | 1993-08-10 | Abdul Majid | Inclusion complexes of cyclodextrins by agglomeration |
| AU616571B2 (en) * | 1988-10-28 | 1991-10-31 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
| JP2954634B2 (ja) * | 1990-02-13 | 1999-09-27 | 協和醗酵工業株式会社 | 化粧料 |
| US5079003A (en) * | 1990-03-14 | 1992-01-07 | Adelia Scaffidi | Skin lotions and creams |
| SE9300971D0 (sv) * | 1993-03-24 | 1993-03-24 | Jan Wadstein | Hudvaardskomposition |
-
1996
- 1996-11-15 SE SE9604193A patent/SE520645C2/sv not_active IP Right Cessation
-
1997
- 1997-11-14 IL IL12953697A patent/IL129536A0/xx unknown
- 1997-11-14 CA CA002271268A patent/CA2271268C/en not_active Expired - Fee Related
- 1997-11-14 AT AT97913636T patent/ATE258783T1/de not_active IP Right Cessation
- 1997-11-14 NZ NZ335473A patent/NZ335473A/en unknown
- 1997-11-14 EP EP97913636A patent/EP1014926B1/de not_active Expired - Lifetime
- 1997-11-14 DE DE69727507T patent/DE69727507T2/de not_active Expired - Fee Related
- 1997-11-14 WO PCT/SE1997/001921 patent/WO1998022083A1/en not_active Ceased
- 1997-11-14 PL PL97333209A patent/PL333209A1/xx unknown
- 1997-11-14 AU AU50773/98A patent/AU727291B2/en not_active Ceased
-
1999
- 1999-04-28 NO NO19992030A patent/NO313616B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998022083A1 (en) | 1998-05-28 |
| NO313616B1 (no) | 2002-11-04 |
| IL129536A0 (en) | 2000-02-29 |
| PL333209A1 (en) | 1999-11-22 |
| ATE258783T1 (de) | 2004-02-15 |
| CA2271268A1 (en) | 1998-05-28 |
| AU5077398A (en) | 1998-06-10 |
| NO992030D0 (no) | 1999-04-28 |
| AU727291B2 (en) | 2000-12-07 |
| SE9604193L (sv) | 1998-05-16 |
| NZ335473A (en) | 2001-02-23 |
| EP1014926A1 (de) | 2000-07-05 |
| DE69727507D1 (de) | 2004-03-11 |
| CA2271268C (en) | 2008-07-08 |
| NO992030L (no) | 1999-04-28 |
| DE69727507T2 (de) | 2004-12-16 |
| EP1014926B1 (de) | 2004-02-04 |
| SE9604193D0 (sv) | 1996-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9833461B2 (en) | Therapeutic compositions comprising cannabidiol and corticosteroids | |
| US20040052754A1 (en) | Complexes of phosphate derivatives | |
| CA2910206C (en) | Novel therapeutic composition | |
| AU752586B2 (en) | Therapeutic compositions | |
| JPH05286864A (ja) | 乾癬及びアトピー性皮膚炎治療用の局所適用製剤 | |
| SE520645C2 (sv) | Terapeutiska och kosmetiska kompositioner, deras användning och metod för framställning därav | |
| JP2020023589A (ja) | シェラックベースのスキンケアローション | |
| JP4033981B2 (ja) | テストステロン ５α−リダクターゼ阻害剤 | |
| CN104684538B (zh) | 用于皮肤保湿的化妆品或皮肤病学组合物 | |
| EP0020532B1 (de) | Haut-zusammensetzung auf der basis von lezithin-triäthanolamin | |
| JPH04360820A (ja) | 化粧料 | |
| JP3326059B2 (ja) | 皮膚化粧料 | |
| US10548939B1 (en) | Oat and marigold based composition with anti-inflammatory and wound healing action and method of preparing same | |
| CN115209890B (zh) | 抑制促炎基因表达的紫草素、芳基萘木酚素以及包含它们的药物组合物 | |
| KR100473716B1 (ko) | 7-디하이드로콜레스테롤 및 사이클로덱스트린의 포접복합체, 이를 포함하는 화장료 조성물 및7-디하이드로콜레스테롤의 안정화방법 | |
| JP3792053B2 (ja) | 過酸化脂質生成抑制剤及びこれを含有する組成物 | |
| JP2005281174A (ja) | 活性酸素消去剤 | |
| JP2003246725A (ja) | 洗い流し型化粧料 | |
| KR20220056731A (ko) | 칼라민을 포함하는 화장료 조성물 및 이의 제조방법 | |
| KR20220060036A (ko) | 케라틴을 함유하는 항염증 조성물 | |
| JPH01113314A (ja) | 皮膚外用剤 | |
| JP2004002281A (ja) | 液状化粧料 | |
| CZ2001894A3 (cs) | Léčivé a kosmetické přípravky pro topickou aplikaci | |
| JP2005015389A (ja) | 皮膚外用剤 | |
| HK1037126B (en) | Compositions for the treatment of acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |